Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report

/ / News

Clovis Oncology Inc. stock tumbled more than 14% in after-hours trading Friday after the company said it plans to discontinue the phase-two trial evaluating its rucaparib treatment in bladder cancer, according to a report. Clovis halted the trial due to the recommendation of an independent monitoring committee, according to Dow Jones. Clovis said the committee recommendation wasn’t a result of the “safety profile” of the treatment, according to Dow Jones.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Lifetime Chatroom Membership